Mavacamten

Generic Name: Mavacamten

Brand Names: Camzyos

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₉N_₃O_₂

CAS Number: 1642288-47-8

Unique Ingredient Identifier: QX45B99R3J

Background: Mavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans. Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.

Indication: Mavacamten is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms by the FDA, Health Canada, and the EMA.

Associated Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy

Associated Therapies: -

Clinical Trials

Cytokinetics Educates Docs On Non-Physical Ordeals Of Cardio Condition

Cytokinetics launches 'HCM Beyond the Heart' campaign to educate HCPs on hypertrophic cardiomyopathy's personal burdens, featuring patient stories. The campaign aims to support holistic patient care beyond pharmacotherapeutic treatment, with aficamten expected to be FDA-approved and launched by 2025. The campaign's formal launch is rescheduled for the American Heart Association convention in November.

biopharmadive.com

4 months ago

Novo sinks on obesity drug results; Sanofi reveals anticipated MS data

Novo Nordisk shares fell 6% after mixed Phase 2 weight-loss drug results; Sanofi presented data supporting tolebrutinib for MS; Lasker Awards given to scientists for GLP-1 weight-loss drug research; Edgewise Therapeutics' heart failure drug shows promising early results; FDA declines to approve Vanda Pharmaceuticals' gastroparesis drug; House Energy and Commerce Committee supports extending pediatric rare disease voucher program.

clinicaltrialsarena.com

4 months ago

CAMZYOS offers benefits in oHCM trial

Bristol Myers Squibb presents long-term follow-up results from the EXPLORER-LTE cohort of the MAVA-LTE trial, showing sustained efficacy and safety of CAMZYOS in treating NYHA class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM) over 3.5 years, with consistent improvements in echocardiographic measures and biomarkers, and most patients reaching NYHA class I.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy